In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, […]readmore
Tags : Sepofarsen
Shots: The US FDA has granted RPD designation to Sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10) which is the most common cause of blindness due to genetic […]readmore